Identification and diagnostic value of plasma exosomes miRNA in patients with prostate cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100052722

Enrollment

Unknown

Registered

2021-11-04

Start date

2021-12-01

Completion date

Unknown

Last updated

2022-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Gold Standard:Prostate puncture and postoperative pathological examination

Index test:Plasma&#32

exosomes&#32

miRNA

Eligibility

Sex/Gender

Male

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with prostate cancer by perineal prostate puncture; 2. No history of other tumors; 3. No recent history of urinary tract infection, hepatitis B, tuberculosis, HIV and other chronic diseases; 4. No endocrine therapy, radiochemotherapy and other treatments before surgery.

Exclusion criteria

Exclusion criteria: Unwilling to participate in the research project.

Design outcomes

Primary

Measure	Time frame
Plasma exosomes miRNA;Accuracy, specificity, sensitivity, ROC curve;	—

Countries

China

Contacts

Public ContactTang Kaifa

Affiliated Hospital of Guizhou Medical University

tangkaifa@gmc.edu.cn+86 15285182092

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026